Business Wire

LähiTapiola Deploys Guidewire InsuranceSuite to Support Strategic Development

9.10.2018 12:00:00 EEST | Business Wire | Press release

Share

The LähiTapiola Group, Finnish mutual group of companies, and Guidewire Software, Inc. (NYSE:GWRE), provider of the industry platform general insurers rely upon, today announced that LähiTapiola is deploying Guidewire InsuranceSuite™. LähiTapiola is one of the leading Non-Life insurance companies in Finland. The InsuranceSuite implementation will support them in streamlining and rationalizing multiple, overlapping core systems as well as strengthening customer service and product delivery.

LähiTapiola is gradually replacing its current legacy systems in three phases. All Non-Life new business will be run on InsuranceSuite and existing business will be migrated, starting with its Private lines of insurance.

“Following an extensive vendor search LähiTapiola selected Guidewire based on their strong reputation and credibility, the usability of their software, and Proof of Concept results,” said Mikko Vastela, CIO, LähiTapiola. “As part of our strategic programme, and enabled through our InsuranceSuite deployment, we will have a renewed core system suite that can deliver a range of efficiencies and improvements in user experience both for internal and external users.”

Guidewire InsuranceSuite is enabling LähiTapiola to:

  • Improve cost efficiency by harmonizing and automating operational processes;
  • Provide new systems functionality through modern processes and interfaces; and
  • Proactively deliver simpler, more flexible products to enhance customer service, and support increased acquisition and retention.

“With InsuranceSuite we will be able to provide an improved customer experience with more tailored products and services,” commented Christine Dahlman, Program Director, LähiTapiola. “We will also be better positioned to respond to developing insurance needs and generate a competitive advantage for our business.”

“We congratulate LähiTapiola on their initial deployment and look forward to continuing our work together,” said Sheridon Glenn, vice president, Field Consulting, EMEA, Guidewire Software. “The effort to transform their core systems and offer modern products and services to their customers is in keeping with their stated corporate goals. We are honoured to contribute to this endeavour.”

About Guidewire InsuranceSuite

Guidewire InsuranceSuite is a complete set of core systems and complementary modules combined to form the ideal technology platform that delivers on supporting your critical requirements, for all lines of business, while promoting sales, service, and underwriting excellence across your organization. Guidewire InsuranceSuite is a proven solution that has helped insurers worldwide significantly enrich customer and agent/broker relationships while simultaneously growing profitably and enabling agile responses to market threats and opportunities. InsuranceSuite provides a complete set of systems to support your core operations—underwriting, policy administration, billing, and claims management—to deliver the technology you need to successfully and continually advance your products, processes, and customer relationships. InsuranceSuite’s comprehensive components are built on a common platform, Guidewire InsurancePlatform™, that covers the entire insurance lifecycle while providing the deep functionality required for you to adapt and succeed in a time of rapid industry change.

About LähiTapiola

LocalTapiola Group is a mutual group of companies owned by its customers. LocalTapiola's mission is to safeguard its owner-customers' lives and success. Our vision is to offer Finnish people a safer and healthier life. The lifelong security concept means comprehensive and proactive services. LocalTapiola serves private customers, farmers, entrepreneurs, corporate customers, and organisations.

The number of owner-customers is approximately 1.6 million. The Group consists of 20 regional mutual insurance companies, as well as the national companies, LocalTapiola General, LocalTapiola Life, LocalTapiola Asset Management, and LocalTapiola Real Estate Asset Management. LocalTapiola employs approximately 3,400 people, half of whom work in the regional companies.

www.lahitapiola.fi/localtapiola

About Guidewire Software

Guidewire delivers the industry platform that general insurers rely upon to adapt and succeed in a time of accelerating change. We provide the software, services, and ecosystem to enable our customers to run, differentiate, and grow their business. We are privileged to serve more than 350 general insurers in 32 countries. For more information, please visit https://www.guidewire.com. Follow us on twitter: @Guidewire_PandC.

NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LähiTapiola
Christine Dahlman, +358405073599
Program Director
christine.dahlman@lahitapiola.fi
or
onechocolate Communications
Daniel Couzens, +44 (0)20 7437 0227
guidewire@onechocolatecomms.co.uk
or
Guidewire Software (UK) Ltd
Louise Bradley, +44 (0)7474 837 860
lbradley@guidewire.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye